Since then, the integration of diagnosis and therapy has become common, with recent advancements targeting somatostatin receptors in neuroendocrine tumors, HER2 antigens in BC, and Prostate-specific membrane antigen (PSMA) in prostate cancer [20–22]. Here, FOLH1 is linked to prostate cancer.